Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2018

Open Access 01-12-2018 | Original research

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods

Authors: Mark R. Battle, Lovena Chedumbarum Pillay, Val J. Lowe, David Knopman, Bradley Kemp, Christopher C. Rowe, Vincent Doré, Victor L. Villemagne, Christopher J. Buckley

Published in: EJNMMI Research | Issue 1/2018

Login to get access

Abstract

Introduction

A standardised method for quantifying β-amyloid PET tracers would allow comparison across different tracers and different sites. The development of the Centiloid scale has aimed to achieve this, applying a common scale to better aid the diagnosis and prognosis of Alzheimer’s disease (AD) and to monitor anti-amyloid therapeutic interventions. Here, we apply the Centiloid method to [18F]flutemetamol and [11C]PiB (PiB, Pittsburgh compound B) PET images and derive the scaling factor to express their binding in Centiloids.

Methods

Paired PiB and [18F]flutemetamol scans for 74 subjects, including 24 young healthy controls (37 ± 5 years), were analysed using the standard Centiloid method. The same subjects were also analysed using PMOD- and FSL-based pipelines as well as SPM8. Test-retest analysis of 10 AD subjects was also performed with each pipeline.

Results

The standard uptake value ratios (SUVR), determined using the standard SPM8 Centiloid process, showed a strong correlation between [18F]flutemetamol (Flute) and PiB binding (SUVR-Flute = 0.77 × SUVR-PiB + 0.22, R2 = 0.96). Application of the standard Centiloid process allowed the calculation of a direct conversion equation for SUVR-Flute to Centiloid units (CL) (CL = (121.42*SUVR-Flute) − 121.16). Analysis of the data via the two alternate Centiloid pipelines allowed us to derive standardised, SPM8-equivalent equations for both PMOD (CL = (115.24*SUVR-Flute) − 107.86) and FSL (CL = (120.32*SUVR-Flute) − 112.75) respectively. Test-retest analysis of 10 AD subjects showed an approximate 2% difference for each pipeline.

Conclusions

[18F]flutemetamol data can now be expressed in Centiloid units, enhancing its utility in clinical and research applications for β-amyloid imaging. The standard Centiloid method also demonstrates that [18F]flutemetamol has favourable performance compared with PiB and other β-amyloid tracers. Test-retest difference averaged 2%, with no difference between image processing pipelines. Centiloid scaling is robust and can be implemented on a number of platforms.
Literature
1.
Mirra S, Heyman A, McKeel D, Sumi S, Crain B, Brownlee L, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–86.CrossRefPubMed
2.
3.
Mathis C, Wang Y, Holt D, Huang G, Debnath M, Klunk W. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.CrossRefPubMed
4.
Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.CrossRefPubMed
5.
Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci. 2015;36:297–309.CrossRefPubMed
6.
7.
8.
9.
10.
Klunk W, Koeppe R, Price J, Benzinger T, Devous M Sr, Jagust W, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1–15 e1–4.CrossRefPubMed
11.
Rowe C, Dore V, Jones G, Baxendale D, Mulligan R, Bullich S, et al. (18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44:2053–9.CrossRefPubMedPubMedCentral
12.
Rowe C, Jones G, Dore V. Standardized expression of 18F-NAV4694 and 11C-PiB Beta-amyloid PET results with the Centiloid scale. J Nucl Med. 2016;57:1233–7.CrossRefPubMed
13.
Navitsky M, Joshi A, Devous M Sr, Pontecorvo M, Lu M, Klunk W, et al. Conversion of amyloid quantitation with Florbetapir SUVR to the Centiloid scale. Alzheimers Dement. 2016;12:25–6.CrossRef
14.
Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.CrossRefPubMed
15.
Lowe VJ, Lundt E, Knopman D, Senjem ML, Gunter JL, Schwarz CG, et al. Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer’s disease dementia individuals. Neuroimage Clin. 2017;16:295–302.CrossRefPubMedPubMedCentral
16.
Miki T, Shimada H, Kim JS, Yamamoto Y, Sugino M, Kowa H, et al. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subjects with amnestic mild cognitive impairment and healthy volunteers. Ann Nucl Med. 2017;31:260–72.CrossRefPubMedPubMedCentral
17.
Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143–56.CrossRefPubMed
18.
Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002;17:825–41.CrossRefPubMed
19.
20.
Andersson J, Jenkinson M, Smith S. Non-linear registration. FMRIB Technial Report TR07JA2. 2007.
21.
22.
McNamee R, Yee S, Price J, Klunk W, Rosario B, Weissfeld L, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med. 2009;50:348–55.CrossRefPubMed
23.
Klumpers U, Boellaard R, Veltman D, Kloet R, Hoogendijk W, Lammertsma A. Parametric [11C]flumazenil images. Nucl Med Commun. 2012;33:422–30.CrossRefPubMed
24.
Metadata
Title
Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
Authors
Mark R. Battle
Lovena Chedumbarum Pillay
Val J. Lowe
David Knopman
Bradley Kemp
Christopher C. Rowe
Vincent Doré
Victor L. Villemagne
Christopher J. Buckley
Publication date
01-12-2018
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2018
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-018-0456-7

Other articles of this Issue 1/2018

EJNMMI Research 1/2018 Go to the issue

Original research

Hallmarks in prostate cancer imaging with Ga68-PSMA-11-PET/CT with reference to detection limits and quantitative properties

Original research

90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer

Original research

A new methodology to derive 3D kinetic parametric FDG PET images based on a mathematical approach integrating an error model of measurement

Original research

Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications

Original research

The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist

Original research

Presurgical localization of infected avascular bone segments in chronic complicated posttraumatic osteomyelitis in the lower extremity using dual-tracer PET/CT